Hepatitis C virus modified sE2 F442NYT as an antigen in candidate vaccine facilitates human immune cell activation.
Yuki HagaKeith MeyerMolly M H SungErin K ReaganDrew WeissmanRanjit RayPublished in: Journal of virology (2023)
may further strengthen the efficacy of the candidate vaccine in evaluating it for human use.